To Treat or Not to Treat: Are We Sacrificing Treatment Outcomes by Allowing Diabetic Retinopathy (DR) to Enter the Proliferative Stage?

Related

• 

  6-Month Results of a Phase 1b-2 Prospective Multicenter Clinical Trial of a Novel Targeted Therapy (AU-011) for the Treatment of Choroidal Melanoma

  Amy C. Schefler, MD FACS FASRS

  Annual Meeting Talks

  2018

• 

  Part 3: Implementing Clinical Trials in a Retina Practice: How to Get Started and Recruit Successfully (Part 3 of 3)

  Arshad M. Khanani, MD, MA, FASRS

  Carl J Danzig, MD

  Charles C Wykoff, MD, PhD, FASRS

  John D Pitcher, MD

  Nikolas JS London, MD, FACS, FASRS

  On Demand Cases, Courses, and Papers

  2018

• 

  Utility of Hypersonic Vitrector Settings During Vitreoretinal Surgery

  Sunir J. Garg, MD, FACS, FASRS

  Annual Meeting Talks

  2018